ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P ASX 200
7,724.30
-0.33%
S&P ASX All Technology
3,092.70
-1.13%
Brent Oil
82.275
0.00%
US Dollar vs AUD
1.51378
0.08%
Bitcoin
66,017.29
0.02%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Allogene Therapeutics Inc (ALLO)

  7. Allogene Therapeutics Inc (ALLO) News

ALLO Allogene Therapeutics Inc

2.3418
-0.1982 (-7.80%)
15 Jun 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Stock Type
Allogene Therapeutics Inc ALLO NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
Upgrade Icon
-0.1982 -7.80% 2.3418 14:00:03
Open Price Low Price High Price Close Price Previous Close
2.52 2.32 2.525 2.35 2.54
more quote information »

Recent News

Date Time Source Heading
12/6/202406:10EDGAR2Form 3 - Initial statement of beneficial ownership of..
11/6/202406:30EDGAR2Form 8-K - Current report
08/6/202407:35EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/6/202407:34EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/6/202407:25EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/5/202422:30GLOBEAllogene Therapeutics Announces Participation in the TD..
15/5/202406:40EDGAR2Form 8-K - Current report
15/5/202406:38EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
14/5/202406:47GLOBEAllogene Therapeutics Announces Pricing of $110 million..
14/5/202406:03EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
14/5/202406:02EDGAR2Form 8-K - Current report
14/5/202406:01GLOBEAllogene Therapeutics Reports First Quarter 2024 Financial..
06/5/202422:30GLOBEAllogene Therapeutics to Report First Quarter Financial..
26/4/202422:30GLOBEAllogene Therapeutics Awarded Grant from the California..
09/4/202422:30GLOBEAllogene Therapeutics Announces Q2 Investor Conference..
15/3/202407:05GLOBEAllogene Therapeutics Reports Fourth Quarter and Full Year..
12/3/202423:30GLOBEAllogene Therapeutics and Arbor Biotechnologies Announce..
06/3/202400:30GLOBEAllogene Therapeutics to Report Fourth Quarter and Full Year..
29/2/202400:30GLOBEAllogene Therapeutics Announces Participation in the 44th..
17/2/202400:30EDGAR2Form 8-K - Current report
17/2/202400:30GLOBEAllogene Therapeutics to Restate Previously Filed Financial..
01/2/202409:45EDGAR2Form 4 - Statement of changes in beneficial ownership of..
25/1/202409:25EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/1/202408:11EDGAR2Form 144 - Report of proposed sale of securities
17/1/202408:05GLOBEAllogene Therapeutics Announces Participation in Upcoming..
06/1/202400:00EDGAR2Form 8-K - Current report
05/1/202408:15GLOBEAllogene Therapeutics and Foresight Diagnostics Announce..
05/1/202408:05GLOBEAllogene Therapeutics Announces 2024 Platform Vision to..
04/1/202408:05GLOBEAllogene Therapeutics to Host Conference Call Previewing its..
21/12/202308:26EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/12/202307:46EDGAR2Form 8-K - Current report
19/12/202308:17EDGAR2Form 144 - Report of proposed sale of securities
10/12/202304:00GLOBEAllogene Therapeutics Presents Comprehensive Safety Data of..
02/12/202300:30GLOBEAllogene Therapeutics Announces Participation in December..
04/11/202303:00GLOBEAllogene Therapeutics Presents Preclinical Data on a Novel..
03/11/202307:41EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
03/11/202307:06EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
03/11/202307:03EDGAR2Form 8-K - Current report
03/11/202307:02GLOBEAllogene Therapeutics Reports Third Quarter 2023 Financial..
03/11/202300:00GLOBEAllogene Therapeutics Announces Poster Presentations at the..
30/10/202323:30GLOBEAllogene Therapeutics Announces Participation in November..
26/10/202323:30GLOBEAllogene Therapeutics to Report Third Quarter 2023 Financial..
18/10/202307:34EDGAR2Form 8-K/A - Current report: [Amend]
16/10/202323:31EDGAR2Form 8-K - Current report
16/10/202323:30GLOBEAllogene Therapeutics Appoints Geoffrey Parker as Chief..
27/9/202323:09GLOBEAllogene Therapeutics Announces Three Poster Presentations..
05/9/202322:30GLOBEAllogene Therapeutics Announces Participation in September..
15/8/202309:59EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/8/202322:30GLOBEAllogene Therapeutics Appoints Earl Douglas as General..
10/8/202306:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..

Your Recent History

NASDAQ
ALLO
Allogene Therapeutics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved